DDInter1938 DDInter1578
Vincristine is a vinca alkaloid with formula C46H56N4O10 found in the Madagascar periwinkle, Catharanthus roseus. It is used (commonly as the corresponding sulfate salt)as a chemotherapy drug for the treatment of leukaemia, lymphoma, myeloma, breast cancer and head and neck cancer. It has a role as a tubulin modulator, a microtubule-destabilising agent, a plant metabolite, an antineoplastic agent and a drug. It is a methyl ester, an acetate ester, a tertiary alcohol, a member of formamides, an organic heteropentacyclic compound, an organic heterotetracyclic compound, a tertiary amino compound and a vinca alkaloid. It is a conjugate base of a vincristine(2+). It derives from a hydride of a vincaleukoblastine.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends on an RNA-dependent RNA polymerase (RdRp) enzyme complex for genomic replication, which can be inhibited by a class of drugs known as nucleoside analogues. Remdesivir (GS-5734) is an adenosine triphosphate analogue first described in the literature in 2016 as a potential treatment for Ebola.[A191379, A222393] Broad antiviral activity of remdesivir is suggested by its mechanism of action, and to date, it has demonstrated _in vitro_ activity against the _Arenaviridae_, _Flaviviridae_, _Filoviridae_, _Paramyxoviridae_, _Pneumoviridae_, and _Coronaviridae_ viral families. Remdesivir activity against the _Coronaviridae_ family was first demonstrated in 2017, leading to considerable interest in remdesivir as a possible treatment for COVID-19.[A191427, A198810] Remdesivir was confirmed as a non-obligate chain terminator of RdRp from SARS-CoV-2 and the related SARS-CoV and MERS-CoV, and has been investigated in multiple COVID-19 clinical trials.[L12174, L12177] After initially being granted an FDA Emergency Use Authorization (EUA) on May 1st, 2020, remdesivir was fully approved by the FDA for the treatment of COVID-19 on October 22, 2020. Remdesivir is currently marketed under the trademark name VEKLURY by Gilead Sciences Inc. Remdesivir was also approved by the European Commission on July 3, 2020. Remdesivir in combination with [baricitinib] for the treatment of COVID-19, was granted an FDA Emergency Use Authorization on November 19, 2020.
Vincristine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Pioglitazone
Pioglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Vincristine {u} (Compound) upregulates {v} (Gene) PPARD
PPARD {u} (Gene) is upregulated by {v} (Compound) Pioglitazone
Pioglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Vincristine {u} (Compound) causes {v} (Side Effect) Acute coronary syndrome
Acute coronary syndrome {u} (Side Effect) is caused by {v} (Compound) Pioglitazone
Pioglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Vincristine {u} (Compound) downregulates {v} (Gene) NET1
NET1 {u} (Gene) is upregulated by {v} (Compound) Simvastatin
Simvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Vincristine {u} (Compound) downregulates {v} (Gene) NET1
NET1 {u} (Gene) is downregulated by {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Vincristine {u} (Compound) causes {v} (Side Effect) Vertigo
Vertigo {u} (Side Effect) is caused by {v} (Compound) Hydroxychloroquine
Hydroxychloroquine {u} may lead to a major life threatening interaction when taken with {v} Remdesivir
Vincristine {u} (Compound) upregulates {v} (Gene) STK10
STK10 {u} (Gene) is bound by {v} (Compound) Sorafenib
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Vincristine {u} (Compound) upregulates {v} (Gene) CDKN1A
CDKN1A {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Vincristine {u} (Compound) downregulates {v} (Gene) TOP2A
TOP2A {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is downregulated by {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Vincristine {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) TUBB6
TUBB6 {u} (Gene) is downregulated by {v} (Compound) Simvastatin
Simvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Vincristine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Pioglitazone (Compound) and Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Vincristine (Compound) upregulates PPARD (Gene) and PPARD (Gene) is upregulated by Pioglitazone (Compound) and Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Vincristine (Compound) causes Acute coronary syndrome (Side Effect) and Acute coronary syndrome (Side Effect) is caused by Pioglitazone (Compound) and Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Vincristine (Compound) downregulates NET1 (Gene) and NET1 (Gene) is upregulated by Simvastatin (Compound) and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Vincristine (Compound) downregulates NET1 (Gene) and NET1 (Gene) is downregulated by Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Vincristine (Compound) causes Vertigo (Side Effect) and Vertigo (Side Effect) is caused by Hydroxychloroquine (Compound) and Hydroxychloroquine may lead to a major life threatening interaction when taken with Remdesivir
Vincristine (Compound) upregulates STK10 (Gene) and STK10 (Gene) is bound by Sorafenib (Compound) and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Vincristine (Compound) upregulates CDKN1A (Gene) and CDKN1A (Gene) is downregulated by Vemurafenib (Compound) and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Vincristine (Compound) downregulates TOP2A (Gene) and TOP2A (Gene) is bound by Epirubicin (Compound) and TOP2A (Gene) is downregulated by Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Vincristine (Compound) binds TUBB6 (Gene) and Vincristine (Compound) upregulates TUBB6 (Gene) and TUBB6 (Gene) is downregulated by Simvastatin (Compound) and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir